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Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing 
Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was 
published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the 
Alert, NIOSH identified a sample list of major hazardous drugs. The list was compiled from infor­
mation provided by four institutions that have generated lists of hazardous drugs for their respec­
tive facilities and by the Pharmaceutical Research and Manufacturers of America (PhRMA) from 
the American Hospital Formulary Service Drug Information (AHFS DI) monographs [ASHP/ 
AHFS DI 2003]. This update adds 21 drugs to the original list in the 2004 Alert. These additions are 
new drugs or existing drugs that had new warnings from 2004 to 2007. The review process for the 
addition of the new listings is described in the Federal Register: http://www.cdc.gov/niosh/docket/ 
pdfs/NIOSH-105-A/0105-A-042909-FR_Notice.pdf
AppENDix A • Drugs CoNSiDERED Hazardous
General Approach to Handling 
Hazardous Drugs
In this Alert, NIOSH presents a standard pre­
cautions or universal precautions approach 
to handling hazardous drugs safely: that is, 
NIOSH recommends that all hazardous drugs 
be handled as outlined in this Alert. Therefore, 
no attempt has been made to perform drug 
risk assessments or propose exposure limits. 
The area of new drug development is rapidly 
evolving as unique approaches are being taken 
to treat cancer and other serious diseases.
Defining Hazardous Drugs
Hazardous drugs include those used for can­
cer chemotherapy, antiviral drugs, hormones, 
some bioengineered drugs, and other miscella­
neous drugs. The definition of hazardous drugs 
used in this Alert is based on an ASHP defi­
nition that was originally developed in 1990 
[ASHP 1990]. Thus the definition may not ac­
curately reflect the toxicity criteria associated 
with the newer generation of pharmaceuticals 
entering the health care setting. For example, 
bioengineered drugs target specific sites in the
body; and although they may or may not be 
toxic to the patient, some may not pose a risk 
to health care workers.
NIOSH and other organizations are still gath­
ering data on the potential toxicity and health 
effects related to highly potent drugs and bio­
engineered drugs. Therefore, when working 
with any hazardous drug, health care workers 
should follow a standard precautions approach 
along with any recommendations included in 
the manufacturer’s MSDSs.
ASHP Definition of Hazardous 
Drugs
The ASHP defines hazardous drugs in their 
1990 revision of Technical Assistance Bulletin on 
Handling Hazardous Drugs [ASHP 1990]. The 
bulletin gives criteria for identifying poten­
tially hazardous drugs that should be handled 
in accordance with an established safety pro­
gram [McDiarmid et al. 1991; Arrington and 
McDiarmid 1993]. The criteria are prioritized 
to reflect the hierarchy of potential toxicity de­
scribed below. Since the hazardous drugs cov­
ered by this Alert were designed as therapeu­
tic agents for humans, human toxicity profiles
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should be considered superior to any data from 
animal models or in vitro systems. Additional 
guidance for defining hazardous drugs is avail­
able in the following citations: carcinogenicity 
[61 Fed. Reg. 17960-18011 (1996b); IARC 2010], 
teratogenicity [56 Fed. Reg. 63798-63826 
(1991)], developmental toxicity [56 Fed. Reg. 
63798-63826 (1991)], and reproductive toxic­
ity [61 Fed. Reg. 56274-56322 (1996a)]. Physi­
cal characteristics of the agents (such as liquid 
versus solid, or water versus lipid solubility) 
also need to be considered in determining the 
potential for occupational exposure.
NIOSH Revision of ASHP Definition
The 1990 ASHP definition of hazardous drugs* 
was revised by the NIOSH Working Group on 
Hazardous Drugs for this Alert. Drugs consid­
ered hazardous include those that exhibit one 
or more of the following six characteristics in 
humans or animals:
1. Carcinogenicity
2. Teratogenicity or other developmental tox­
ic ^
*ASHP [1990] definition of hazardous drugs:1. Carcinogenicity2. Teratogenicity or other developmental toxicity3. Reproductive toxicity4. Organ toxicity at low doses5. Genotoxicity6. Structure and toxicity profiles of new drugs thatmimic existing drugs determined hazardous by the above criteria.
+All drugs have toxic side effects, but some exhibit toxic­ity at low doses. The level of toxicity reflects a contin­uum from relatively nontoxic to production of toxic effects in patients at low doses (for example, a few milligrams or less). For example, a daily therapeutic dose of 10 mg/day or a dose of 1 mg/kg per day in laboratory animals that produces serious organ tox­icity, developmental toxicity, or reproductive toxic­ity has been used by the pharmaceutical industry to develop occupational exposure limits (OELs) of less than 10 ^g/m 3 after applying appropriate uncertainty
3. Reproductive toxicity*
4. Organ toxicity at low doses*
5. Genotoxicity*
Structure and toxicity profiles of new drugs 
that mimic existing drugs determined hazard­
ous by the above criteria
Determining Whether a Drug is 
Hazardous
Many hazardous drugs used to treat cancer 
bind to or damage DNA (for example, alkylat­
ing agents). Other antineoplastic drugs, some 
antivirals, antibiotics, and bioengineered drugs 
interfere with cell growth or proliferation, or 
with DNA synthesis. In some cases, the non- 
selective actions of these drugs disrupt the 
growth and function of both healthy and dis­
eased cells, resulting in toxic side effects for 
treated patients. These nonselective actions 
can also cause adverse effects in health care 
workers who are inadvertently exposed to haz­
ardous drugs.
Early concerns about occupational exposure to 
antineoplastic drugs first appeared in the 1970s. 
Although the antineoplastic drugs remain the 
principal focus of this Alert, other drugs may 
also be considered hazardous because they are 
potent (small quantities produce a physiologi­
cal effect) or cause irreversible effects. As the 
use and number of these potent drugs increase,
factors [Sargent and Kirk 1988; Naumann and Sar­gent 1997; Sargent et al. 2002]. OELs in this range are typically established for potent or toxic drugs in the pharmaceutical industry. Under all circumstances, an evaluation of all available data should be conducted to protect health care workers.
*In evaluating mutagenicity for potentially hazardous drugs, responses from multiple test systems are need­ed before precautions can be required for handling such agents. The EPA evaluations include the type of cells affected and in vitro versus in vivo testing [51 Fed. Reg. 34006-34012 (1986)].
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so do opportunities for hazardous exposures 
among health care workers. For example, an­
tineoplastic drugs such as cyclophosphamide 
have immunosuppressant effects that proved 
beneficial for treating nonmalignant diseas­
es such as rheumatoid arthritis and multiple 
sclerosis [Baker et al. 1987; Moody et al. 1987; 
Chabner et al. 1996; Abel 2000].
This document presents criteria and sources of 
information for determining whether a drug 
is hazardous. When a drug has been judged to 
be hazardous, the various precautions outlined 
the Alert should be applied when handling that 
drug. Also included is a list of drugs that should 
be handled as hazardous. This list is based on 
a compilation of lists from four health care fa­
cilities, one drug manufacturers’ organization, 
and NIOSH.
In addition to using the list of hazardous drugs 
presented here, each organization should cre­
ate its own list of drugs considered to be haz­
ardous. This document presents guidance for 
making such a facility-specific list (see section 
entitled How to Generate your own List o f H az­
ardous Drugs). Once this list is made, newly 
purchased drugs should be evaluated against 
the organization’s hazardous drug criteria and 
added to the list if they are deemed hazardous.
Some organizations may have inadequate 
resources for determining their own list of 
hazardous drugs. If so, the sample list of haz­
ardous drugs in this document (current only 
to the printing date of this document) will 
help employers and workers to determine 
when precautions are needed. However, re­
liance on such a published list is a concern 
because it quickly becomes outdated as new 
drugs continually enter the market or listed 
drugs are removed when additional infor­
mation becomes available. To fill this knowl­
edge gap, NIOSH will update an internet list 
periodically, adding new drugs considered 
to be hazardous and removing those that re­
quire reclassification. This hazardous drug 
list will be posted on the NIOSH Web site at 
www.cdc.gov/niosh.
How to Generate Your Own List of 
Hazardous Drugs
The OSHA hazard communication standard 
[29 CFR 1910.1200] requires employers to 
develop a hazard communication program 
appropriate for their unique workplace. An 
essential part of the program is the identifi­
cation of all hazardous drugs a worker may 
encounter in the facility. Compliance with 
the OSHA hazard communication standard 
entails (1) evaluating whether these drugs 
meet one or more of the criteria for defining 
hazardous drugs and (2) posting a list of the 
hazardous drugs to ensure worker safety. In­
stitutions may wish to compare their lists to 
the sample listing in this document or on the 
NIOSH Web site.
It is not likely that every health care provider 
or facility will use all drugs that have received 
U.S. Food and Drug Administration (FDA) ap­
proval, and the OSHA hazard communication 
standard does not mandate evaluation of every 
marketed drug. Instead, compliance requires 
practice-specific assessments for drugs used at 
any one time by a facility. However, hazardous 
drug evaluation is a continual process. Local 
hazard communication programs should pro­
vide for assessment of new drugs as they enter 
the marketplace, and when appropriate, reas­
sessment of their presence on hazardous drug 
lists as toxicological data become available to 
support recategorization. Toxicological data 
are often incomplete or unavailable for inves­
tigational drugs. However, if the mechanism of 
action suggests that there may be a concern, it 
is prudent to handle them as hazardous drugs 
until adequate information becomes available 
to exclude them.
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Some drugs defined as hazardous may not pose 
a significant risk of direct occupational exposure 
because of their dosage formulation (for ex­
ample, coated tablets or capsules—solid, intact 
medications that are administered to patients 
without modifying the formulation). However, 
they may pose a risk if solid drug formulations 
are altered, such as by crushing tablets or making 
solutions from them outside a ventilated cabinet.
Where to Find Information Related 
to Drug Toxicity
Practice-specific lists of hazardous drugs (usu­
ally developed by pharmacy or nursing depart­
ments) should be comprehensive, including all 
hazardous medications routinely used or very 
likely to be used by a local practice. Some of 
the resources that employers can use to evalu­
ate the hazard potential of a drug include, but 
are not limited to, the following:
■ MSDSs
■ Product labeling approved by the U.S. 
FDA (package inserts)
■ Special health warnings from drug man­
ufacturers, FDA, and other professional 
groups and organizations
■ Reports and case studies published in 
medical and other health care profession 
journals
■ Evidence-based recommendations from 
other facilities that meet the criteria defin­
ing hazardous drugs
Examples of Hazardous Drugs
The following list contains a sampling of major 
hazardous drugs. The list was compiled from
information provided by (1) four institutions 
that have generated lists of hazardous drugs 
for their respective facilities, (2) the American 
Hospital Formulary Service Drug Informa­
tion (AHFS DI) monographs [ASHP/AHFS 
DI 2003], and (3) a NIOSH review of new drug 
approvals and new drug warning from 2004 to 
2007. This review resulted in the addition of 21 
new entries to the list. The OSHA hazard com­
munication standard requires hazardous drugs 
to be handled using special precautions. The 
mandate applies not only to health care profes­
sionals who provide direct patient care but also 
to others who support patient care by partici­
pating in product acquisition, storage, trans­
portation, housekeeping, and waste disposal. 
Institutions may want to adopt this list or com­
pare theirs with the list on the NIOSH Web site.
Caution: Drugs purchased and used by a facil­
ity may have entered the marketplace after the 
list below was assembled. Therefore, this list 
may not be all-inclusive.
If you use a drug that is not included in the 
list of examples, check the available literature 
to see whether the unlisted drug should be 
treated as hazardous. Check the MSDS or the 
proper handling section of the package insert; 
or check with other institutions that might be 
using the same drug. If any of the documents 
mention carcinogenicity, genotoxicity, tera­
togenicity, or reproductive or developmental 
toxicity, use the precautions stipulated in this 
Alert. If a drug meets one or more of the cri­
teria for hazardous drugs listed in this Alert, 
handle it as hazardous.
The listing below will be updated periodically 
on this website.
The attached list of hazardous drugs super­
sedes the 2004 list: http://www.cdc.gov/niosh/ 
docs/2004-165/
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Sample List of Drugs that Should be Handled as Hazardous*
Drug Source
AHFS Pharmalocologic-therapeutic 
classification
Aldesleukin 4,5 10:00 Antineoplastic agents
Alefacept 6 84:92 Miscellaneous skin and mucous 
membrane agents
Alemtuzumab 1,3,4,5 10:00 Antineoplastic agents
Alitretinoin 3,4,5 84:36 Miscellaneous skin and mucous 
membrane agents (retinoid)
Altretamine 1,2,3,4,5 10:00 Antineoplastic agents
Amsacrine 3,5 Not in AHFS (antineoplastic agent)
Anastrozole 1,5 10:00 Antineoplastic agents
Arsenic trioxide 1,2,3,4,5 10:00 Antineoplastic agents
Asparaginase 1,2,3,4,5 10:00 Antineoplastic agents
Azacitidine 3,5 10:00 Antineoplastic agents
Azathioprine 2,3,5 92:44 Unclassified therapeutic agents 
(immunosuppressant)
Bacillus Calmette-Guerin 
(BCG)+
1,2,4 80:12 Vaccines
Bexarotene 2,3,4,5 10:00 Antineoplastic agents
Bicalutamide 1,5 10:00 Antineoplastic agents
Bleomycin 1,2,3,4,5 10:00 Antineoplastic agents
Bortezomib 6 10:00 Antineoplastic agents
Bosentan 6 24:12.92 Vasodilating agents
Busulfan 1,2,3,4,5 10:00 Antineoplastic agents
Capecitabine 1,2,3,4,5 10:00 Antineoplastic agents
Carboplatin 1,2,3,4,5 10:00 Antineoplastic agents
Carmustine 1,2,3,4,5 10:00 Antineoplastic agents
Cetrorelix acetate 5 92:40 Unclassified therapeutic agents 
(GnRH antagonist)
Chlorambucil 1,2,3,4,5 10:00 Antineoplastic agents
Chloramphenicol 1,5 8:12.08 Antibacterials
Choriogonadotropin alfa 5 68:18 Gonadotropins
Cidofovir 3,5 8:18.32 Antiviral nucleoside
Cisplatin 1,2,3,4,5 10:00 Antineoplastic agents
Cladribine 1,2,3,4,5 10:00 Antineoplastic agents
Clofarabine 6 10:00 Antineoplastic agents
(Continued)
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Sample List of Drugs that Should be Handled as Hazardous (Continued)
AHFS Pharmalocologic-therapeutic 
Drug Source classification
Colchicine 5 92:16 Unclassified therapeutic agents 
(antigout agents)
Cyclophosphamide 1,2,3,4,5 10:00 Antineoplastic agents
Cyclosporin 1 92:00 Immunosuppressive agents
Cytarabine 1,2,3,4,5 10:00 Antineoplastic agents
Dacarbazine 1,2,3,4,5 10:00 Antineoplastic agents
Dactinomycin 1,2,3,4,5 10:00 Antineoplastic agents
Dasatinib e 10:00 Antineoplastic agents
Daunorubicin HCl 1,2,3,4,5 10:00 Antineoplastic agents
Decitabine e 10:00 Antineoplastic agents
Denileukin 3,4,5 10:00 Antineoplastic agents
Dienestrol 5 68:16.04 Estrogens
Diethylstilbestrol 5 Not in AHFS (nonsteroidal synthetic 
estrogen)
Dinoprostone 5 76:00 Oxytocics
Docetaxel 1,2,3,4,5 10:00 Antineoplastic agents
Doxorubicin 1,2,3,4,5 10:00 Antineoplastic agents
Dutasteride 5 92:08 Unclassified therapeutic agents 
(5-alpha reductase inhibitor)
Entecavir e 8:18.32 Antiviral nucleoside
Epirubicin 1,2,3,4,5 10:00 Antineoplastic agents
Ergonovine/
methylergonovine
5 76:00 Oxytocics
Estradiol 1,5 68:16.04 Estrogens
Estramustine phosphate 1,2,3,4,5 10:00 Antineoplastic agents
Estrogen-progestin
combinations
5 68:12 Contraceptives
Estrogens, conjugated 5 68:16.04 Estrogens
Estrogens, esterified 5 68:16.04 Estrogens
Estrone 5 68:16.04 Estrogens
Estropipate 5 68:16.04 Estrogens
Etoposide 1,2,3,4,5 10:00 Antineoplastic agents
Exemestane 1,5 10:00 Antineoplastic agents
Finasteride 1,3,5 92:08 Unclassified therapeutic agents
(5-alpha reductase inhibitor)
(Continued)
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Sample List of Drugs that Should be Handled as Hazardous (Continued)
AHFS Pharmalocologic-therapeutic 
Drug Source classification
Floxuridine 1,2,3,4,5 10:00 Antineoplastic agents
Fludarabine 1,2,3,4,5 10:00 Antineoplastic agents
Fluorouracil 1,2,3,4,5 10:00 Antineoplastic agents
Fluoxymesterone 5 68:08 Androgens
Flutamide 1,2,5 10:00 Antineoplastic agents
Fulvestrant 5 10:00 Antineoplastic agents
Ganciclovir 1,2,3,4,5 8:18.32 Antiviral nucleoside
Ganirelix acetate 5 92:40 Unclassified therapeutic agents 
(GnRH antagonist)
Gemcitabine 1,2,3,4,5 10:00 Antineoplastic agents
Gemtuzumab ozogamicin 1,3,4,5 10:00 Antineoplastic agents
Gonadotropin, chorionic 5 68:18 Gonadotropins
Goserelin 1,2,5 10:00 Ant neoplastic agents
Hydroxyurea 1,2,3,4,5 10:00 Ant neoplastic agents
Ibritumomab tiuxetan 3 10:00 Ant neoplastic agents
Idarubicin 1,2,3,4,5 10:00 Ant neoplastic agents
Ifosfamide 1,2,3,4,5 10:00 Ant neoplastic agents
Imatinib mesylate 1,3,4,5 10:00 Ant neoplastic agents
Interferon alfa-2a 1,2,4,5 10:00 Ant neoplastic agents
Interferon alfa-2b 1,2,4,5 10:00 Ant neoplastic agents
Interferon alfa-n1 1,5 10:00 Ant neoplastic agents
Interferon alfa-n3 1,5 10:00 Ant neoplastic agents
Irinotecan HCl 1,2,3,4,5 10:00 Ant neoplastic agents
Leflunomide 3,5 92:36 Unclassified therapeutic agents 
(antineoplastic agent)
Lenalidomide 6 92:20 Unclassified therapeutic agents 
(biologic response modifiers)
Letrozole 1,5 10:00 Antineoplastic agents
Leuprolide acetate 1,2,5 10:00 Antineoplastic agents
Lomustine 1,2,3,4,5 10:00 Antineoplastic agents
Mechlorethamine 1,2,3,4,5 10:00 Antineoplastic agents
Medroxyprogesterone
acetate
6 68:32 Progestins
Megestrol 1,5 10:00 Antineoplastic agents
(Continued)
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Sample List of Drugs that Should be Handled as Hazardous (Continued)
Drug Source
AHFS Pharmalocologic-therapeutic 
classification
Melphalan 1,2,3,4,5 10:00 Antineoplastic agents
Menotropins 5 68:18 Gonadotropins
Mercaptopurine 1,2,3,4,5 10:00 Antineoplastic agents
Methotrexate 1,2,3,4,5 10:00 Antineoplastic agents
Methyltestosterone 5 68:08 Androgens
Mifepristone 5 76:00 Oxytocics
Mitomycin 1,2,3,4,5 10:00 Antineoplastic agents
Mitotane 1,4,5 10:00 Antineoplastic agents
Mitoxantrone HCl 1,2,3,4,5 10:00 Antineoplastic agents
Mycophenolate mofetil 1,3,5 92:44 Unclassified therapeutic agents 
(immunosuppressive agents)
Nafarelin 5 68:18 Gonadotropins
Nelarabine 6 10:00 Antineoplastic agents
Nilutamide 1,5 10:00 Antineoplastic agents
Oxaliplatin 1,3,4,5 10:00 Antineoplastic agents
Oxytocin 5 76:00 Oxytocics
Paclitaxel 1,2,3,4,5 10:00 Antineoplastic agents
Palifermin 6 84:16 Cell stimulants
Paroxetine HCl 6 28:16.04.20 Selective seretonin uptake 
inhibitors
Pegaspargase 1,2,3,4,5 10:00 Antineoplastic agents
Pemetrexed 6 10:00 Antineoplastic agents
Pentamidine isethionate 1,2,3,5 8:40 Miscellaneous anti-infectives
Pentetate calcium trisodium 6 Not in AHFS
Pentostatin 1,2,3,4,5 10:00 Antineoplastic agents
Perphosphamide 3,5 Not in AHFS (antineoplastic agent)
Pipobroman 3,5 Not in AHFS (antineoplastic agent)
Piritrexim isethionate 3,5 Not in AHFS (antineoplastic agent)
Plicamycin 1,2,3,5 Not in AHFS (antineoplastic agent)
Podofilox 5 84:92 Miscellaneous skin and mucous 
membrane agents (mitotic 
inhibitor)
Podophyllum resin 5 84:92 Miscellaneous skin and
mucousmembrane agents (mitotic 
inhibitor)
(Continued)
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Sample List of Drugs that Should be Handled as Hazardous (Continued)
Drug Source
AHFS Pharmalocologic-therapeutic 
classification
Prednimustine 3,5 Not in AHFS (antineoplastic agent)
Procarbazine 1,2,3,4,5 10:00 Antineoplastic agents
Progesterone 5 68:32 Progestins
Progestins 5 68:12 Contraceptives
Raloxifene 5 68:16.12 Estrogen agonists-antagonists
Raltitrexed 5 Not in AHFS (antineoplastic agent)
Rasagiline mesylate 6 28:36 Antiparkinsonian agents
Ribavirin 1,2,5 8:18.32 Antiviral nucleoside
Risperidone 6 28:16.08.04 Atypical antipsychotics
Sirolimus 6 92:00 Immunosuppressive agents
Sorafenib 6 10:00 Antineoplastic agents
Streptozocin 1,2,3,4,5 10:00 Antineoplastic agents
Sunitinib malate 6 10:00 Antineoplastic agents
Tacrolimus 1,5 92:44 Unclassified therapeutic agents 
(immunosuppressant)
Tamoxifen 1,2,5 10:00 Antineoplastic agents
Temozolomide 3,4,5 10:00 Antineoplastic agents
Teniposide 1,2,3,4,5 10:00 Antineoplastic agents
Testolactone 5 10:00 Antineoplastic agents
Testosterone 5 68:08 Androgens
Thalidomide 1,3,5 92:20 Unclassified therapeutic agents 
(biologic response modifier)
Thioguanine 1,2,3,4,5 10:00 Antineoplastic agents
Thiotepa 1,2,3,4,5 10:00 Antineoplastic agents
Topotecan 1,2,3,4,5 10:00 Antineoplastic agents
Toremifene citrate 1,5 10:00 Antineoplastic agents
Tositumomab 3,5 10:00 Antineoplastic agents
Tretinoin 1,2,3,5 84:16 Cell stimulants and proliferants 
(retinoid)
Trifluridine 1,2,5 52:04.06 Antivirals
Trimetrexate glucuronate 5 8:30.92 Miscellaneous antiprotozoals
Triptorelin 5 10:00 Antineoplastic agents
Uracil mustard 3,5 Not in AHFS (antineoplastic agent)
Valganciclovir 1,3,5 8:18.32 Antiviral nucleoside
(Continued)
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Sample List of Drugs that Should be Handled as Hazardous (Continued)
Drug Source
AHFS Pharmalocologic-therapeutic 
classification
Valrubicin 1,2,3,5 10:00 Antineoplastic agents
Vidarabine 1,2,5 Not in AHFS
Vinblastine sulfate 1,2,3,4,5 10:00 Antineoplastic agents
Vincristine sulfate 1,2,3,4,5 10:00 Antineoplastic agents
Vindesine 1,5 Not in AHFS (antineoplastic agent)
Vinorelbine tartrate 1,2,3,4,5 10:00 Antineoplastic agents
Vorinostat 6 10:00 Antineoplastic agents
Zidovudine 1,2,5 8:18:08 Antiretroviral agents
Zonisamide 6 28:12.92 Anticonvulsant
*These lists of hazardous drugs were used with the permission of the institutions that provided them  and were 
adapted for use by NIOSH. The sample lists are intended to guide health care providers in diverse practice set­
tings and should not be construed as complete representations of all of the hazardous drugs used at the referenced 
institutions. Some drugs defined as hazardous may not pose a significant risk of direct occupational exposure 
because of their dosage formulation (for example, intact m edications such as coated tablets or capsules that are 
adm inistered to patients without modifying the formulation). However, they may pose a risk if solid drug form u­
lations are altered outside a ventilated cabinet (for example, if tablets are crushed or dissolved, or if capsules are 
pierced or opened).
fBCG preparation should be done using aseptic techniques. To avoid cross-contamination, parenteral drugs should 
not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is 
recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of 
as biohazardous. If preparation cannot be perform ed in a containm ent device, then respiratory protection, gloves 
and a gown should be worn to avoid inhalation or contact with BCG organisms.
1. The NIH Clinical Center, Bethesda, MD (Revised 8/2002). The NIH Health Clinical Center Hazardous Drug
(HD) List is part of the NIH Clinical Center’s hazard com munication program. It was developed in compli­
ance with the OSHA hazard com munication standard [29 CFR 1910.1200] as it applies to hazardous drugs 
used in the workplace. The list is continually revised and represents the diversity of medical practice at the 
NIH Clinical Center; however, its content does not reflect an exhaustive review of all FDA-approved medica­
tions that may be considered hazardous, and it is not intended for use outside the NIH.
2. The Johns Hopkins Hospital, Baltimore, MD (Revised 9/2002).
3. The Northside Hospital, Atlanta, GA (Revised 8/2002).
4. The University of Michigan Hospitals and Health Centers, A nn Arbor, MI (Revised 2/2003)
5. This sample listing of hazardous drugs was compiled by the Pharmaceutical Research and Manufacturers of
America (PhRMA) using inform ation from the AHFS DI monographs published by ASHP in selected AHFS 
Pharmacologic-Therapeutic Classification categories [ASHP/AHFS DI 2003] and applying the definition 
for hazardous drugs. The list also includes drugs from other sources that satisfy the definition for hazard­
ous drugs [PDR 2004; Sweetman 2002; Shepard 2001; Schardein 2000; REPROTOX 2003]. Newly approved 
drugs that have structures or toxicological profiles that m imic the drugs on this list should also be included. 
This list was revised in June 2004.
6. NIOSH addition 2010 updated using ASHP/AHFS DI 2010.
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To receive NIOSH documents or more inform ation about 
occupational safety and health topics, contact NIOSH at
1- 8OO-CDC-INFO (1-800-232-4636)
TTY: 1-888-232-6348 
E-mail: cdcinfo@cdc.gov
or visit the NIOSH Web site at www.cdc.gov/niosh.
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NIOSH eNews by visiting www.cdc.gov/niosh/eNews.
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